Vaxart Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Andy Floroiu

Chief executive officer

US$2.4m

Total compensation

CEO salary percentage	19.4%
CEO tenure	2.1yrs
CEO ownership	n/a
Management average tenure	2.1yrs
Board average tenure	1.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Andy Floroiu's remuneration changed compared to Vaxart's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2022	n/a	n/a	-US$80m
Dec 31 2021	US$2m	US$467k	-US$70m
Sep 30 2021	n/a	n/a	-US$64m
Jun 30 2021	n/a	n/a	-US$54m
Mar 31 2021	n/a	n/a	-US$47m
Dec 31 2020	US$3m	US$220k	-US$32m

Compensation vs Market: Andy's total compensation ($USD2.41M) is above average for companies of similar size in the German market ($USD1.11M).

Compensation vs Earnings: Andy's compensation has been consistent with company performance over the past year.

CEO

Andy Floroiu (49 yo)

2.1yrs

Tenure

US$2,410,175

Compensation

Mr. Cezar Andrei Floroiu, also known as Andy, M.B.A., serves as the Chief Executive Officer at Vaxart, Inc. since June 14, 2020 and served as Principal Financial Officer at Vaxart, Inc. since June 14, 2020...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Cezar Floroiu	CEO, President & Director	2.1yrs	US$2.41m	no data
Sean Tucker	Senior VP & Chief Scientific Officer	12.4yrs	US$1.19m	no data
James Cummings	Chief Medical Officer	less than a year	US$2.38m	no data
Fuad Ahmad	Interim CFO and Principal Financial & Accounting Officer	less than a year	no data	0.0040% € 21.2k
Edward Berg	Senior VP & General Counsel	less than a year	no data	no data
Shaily Garg	Senior Vice President of Clinical Development & Project Management	2.3yrs	no data	no data
Brant Biehn	Senior Vice President of Business Operations	4.3yrs	no data	no data
Rajesh Kapoor	Senior Vice President of Quality	1.5yrs	no data	no data
John Harland	Consultant	3.5yrs	US$418.05k	no data

2.1yrs

Average Tenure

55yo

Average Age

Experienced Management: NB11's management team is considered experienced (2.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Cezar Floroiu	CEO, President & Director	2.3yrs	US$2.41m	no data
Robert Yedid	Lead Independent Director	2.8yrs	US$158.00k	0.0041% € 22.2k
Harry Greenberg	Member of Scientific & Clinical Advisory Board	less than a year	no data	no data
Karen Wilson	Independent Director	1.9yrs	US$158.00k	0% € 0
Todd Davis	Independent Chairman of the Board	2.8yrs	US$171.00k	0.094% € 502.7k
Michael Finney	Independent Director	15.5yrs	US$152.40k	0.52% € 2.8m
Stefan Gravenstein	Member of Scientific & Clinical Advisory Board	less than a year	no data	no data
David Wheadon	Independent Director	1.3yrs	US$485.94k	0% € 0
Robert Belshe	Member of Scientific & Clinical Advisory Board	less than a year	no data	no data
Marion Pepper	Member of Scientific & Clinical Advisory Board	less than a year	no data	no data
Ralph Baric	Member of Scientific & Clinical Advisory Board	less than a year	no data	no data
Gregory Gray	Member of Scientific & Clinical Advisory Board	less than a year	no data	no data

1.1yrs

Average Tenure

62yo

Average Age

Experienced Board: NB11's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.

Vaxart Management

Management criteria checks 2/4

Key information

Recent management updates

Vaxart, Inc., Annual General Meeting, Jun 11, 2024

Vaxart, Inc. Announces Chief Executive Officer Changes

Vaxart, Inc. Announces CEO Changes

Vaxart, Inc. Names Phillip Lee as Chief Financial Officer

Vaxart, Inc. Appoints Ray Stapleton as Chief Technology Officer

Vaxart, Inc. Announces Board Changes

Recent updates

Vaxart, Inc. to Report Q3, 2024 Results on Nov 13, 2024

Vaxart, Inc. Announces Initiation of Sentinel Cohort for Phase 2B Study Evaluating its Covid-19 Oral Pill Vaccine Candidate

Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of Its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for Hpv-Related Cervical Dysplasia

Vaxart, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Vaxart Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market

Vaxart, Inc. Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Vaxart, Inc. to Report Q1, 2024 Results on May 13, 2024

Vaxart, Inc., Annual General Meeting, Jun 11, 2024

Vaxart, Inc. to Report Fiscal Year 2023 Results on Mar 14, 2024

Vaxart, Inc. Announces Chief Executive Officer Changes

Nasdaq Notifies Vaxart's Eligibility for an Additional 180-Day Compliance Period, or Until July 15, 2024, to Regain Compliance with the Bid Price Requirement

Vaxart, Inc. Announces CEO Changes

Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Vaxart, Inc. Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

Vaxart Doses First Subject in Phase 1 Trial of its Norovirus Vaccine Candidate in Lactating Mothers

Vaxart, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Vaxart Announces Topline Data from the Phase 2 Challenge Study of Its Monovalent Norovirus Vaccine Candidate

Vaxart, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Vaxart Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement

Vaxart, Inc. Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate

Vaxart, Inc.(NasdaqCM:VXRT) dropped from Russell 2000 Dynamic Index

Vaxart, Inc. Announces Last Subject Dosed in Phase 2 Trial of Its Bivalent Norovirus Candidate, and All Subjects Challenge Study of Monovalent Norovirus Candidate

Vaxart, Inc. Doses First Subject in the Phase 2 Clinical Trial of Its Bivalent Norovirus Candidate

Vaxart, Inc. Names Phillip Lee as Chief Financial Officer

Vaxart, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Vaxart, Inc. Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate

Vaxart, Inc. Appoints Ray Stapleton as Chief Technology Officer

Vaxart, Inc. Announces Board Changes

Vaxart, Inc. Appoints W. Mark Watson to Its Board of Directors

Vaxart, Inc. Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive

Vaxart, Inc. Presents New Preclinical Data Demonstrate Two of it's COVID-19 Vaccine Candidates Protect Against Omicron

Vaxart Reports Positive Preliminary Data from the Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults

Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 Transmission

Vaxart, Inc. Announces Management Changes

Margaret Echerd Notifies as Senior Vice President and Principal Accounting Officer of Vaxart, Inc, Effective as of May 5, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Vaxart, Inc. Appoints Edward B. Berg as Senior Vice President and General Counsel

High number of new and inexperienced directors

Forecast to breakeven in 2024

High number of new and inexperienced directors

Forecast to breakeven in 2024

Vaxart to Test Cross-Reactivity of Its Covid-19 Oral Tablet Vaccine Against Omicron

No longer forecast to breakeven

High number of new and inexperienced directors

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age